These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 8376690)
1. Role of surrogate end points in the evaluation of drugs for heart failure. Lipicky RJ; Packer M J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):179A-184A. PubMed ID: 8376690 [TBL] [Abstract][Full Text] [Related]
2. Surrogate end points in heart failure. Anand IS; Florea VG; Fisher L J Am Coll Cardiol; 2002 May; 39(9):1414-21. PubMed ID: 11985901 [TBL] [Abstract][Full Text] [Related]
3. Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype? Hanigan S; DiDomenico RJ J Pharm Pract; 2016 Feb; 29(1):46-57. PubMed ID: 26759311 [TBL] [Abstract][Full Text] [Related]
4. Surrogate end points in clinical research: hazardous to your health. Grimes DA; Schulz KF Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552 [TBL] [Abstract][Full Text] [Related]
5. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials. Powers JH Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers and surrogate markers: an FDA perspective. Katz R NeuroRx; 2004 Apr; 1(2):189-95. PubMed ID: 15717019 [TBL] [Abstract][Full Text] [Related]
8. Surrogate end points in heart failure. Lee CR; Adams KF; Patterson JH Ann Pharmacother; 2002 Mar; 36(3):479-88. PubMed ID: 11895063 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers as surrogate end points in heart failure trials. Felker GM Heart Fail Clin; 2011 Oct; 7(4):501-7. PubMed ID: 21925433 [TBL] [Abstract][Full Text] [Related]
10. Imaging surrogate end points in heart failure trials. Bettari L; Borges-Neto S Heart Fail Clin; 2011 Oct; 7(4):509-18. PubMed ID: 21925434 [TBL] [Abstract][Full Text] [Related]
11. The evaluation of the results of clinical trials: surrogate end points and composite end points. Gensini GF; Conti AA Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers and surrogate end points--the challenge of statistical validation. Buyse M; Sargent DJ; Grothey A; Matheson A; de Gramont A Nat Rev Clin Oncol; 2010 Jun; 7(6):309-17. PubMed ID: 20368727 [TBL] [Abstract][Full Text] [Related]
13. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. Prasad V; Kim C; Burotto M; Vandross A JAMA Intern Med; 2015 Aug; 175(8):1389-98. PubMed ID: 26098871 [TBL] [Abstract][Full Text] [Related]
14. Surrogate end points in secondary analyses of cardiovascular trials. Buhr KA Prog Cardiovasc Dis; 2012; 54(4):343-50. PubMed ID: 22226002 [TBL] [Abstract][Full Text] [Related]
15. Virologic and regimen termination surrogate end points in AIDS clinical trials. Gilbert PB; DeGruttola V; Hammer SM; Kuritzkes DR JAMA; 2001 Feb; 285(6):777-84. PubMed ID: 11176916 [TBL] [Abstract][Full Text] [Related]
17. End points in heart failure-are we doing it right? Goenka L; George M; Selvarajan S Eur J Clin Pharmacol; 2017 Jun; 73(6):651-659. PubMed ID: 28280889 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. Kesselheim AS; Myers JA; Avorn J JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684 [TBL] [Abstract][Full Text] [Related]
19. Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective. Packer M Circulation; 2016 Nov; 134(21):1664-1678. PubMed ID: 27881506 [TBL] [Abstract][Full Text] [Related]
20. Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. Packer M Am Heart J; 2000 Apr; 139(4):S202-6. PubMed ID: 10740133 [No Abstract] [Full Text] [Related] [Next] [New Search]